title: Comparison of roxithromycin with co-amoxiclav in patients with sinusitis.
abstract: In an open, randomized study of 60 patients with acute or recurrent sinusitis, the bacteriological and clinical efficacy of roxithromycin 150 mg bd were compared with those of po co-amoxiclav (625 mg) tds. Of 52 patients who underwent sinus puncture for isolation of causative organisms, 48 had pathogens sensitive to both antibiotics. Satisfactory clinical response was obtained in 93.1% (27/29) evaluable patients receiving roxithromycin and 88.8% (24/27) receiving co-amoxiclav. Tolerability was significantly better in the roxithromycin group, with 1/29 (3.4%) patients in this group experiencing gastrointestinal side-effects, compared with 7/27 (25.9%) patients in the co-amoxiclav group (P < 0.05). Although the study had limited power to detect differences, roxithromycin demonstrated clinical, bacteriological and overall efficacy similar to that of co-amoxiclav, but with better tolerability. Roxithromycin thus appears to be an effective and well-tolerated drug for the treatment of acute and recurrent sinusitis.
authors.affiliation: Erythros Hospital, Athens, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Chatzimanolis
authors.forename: N
authors.initials: N
authors.lastname: Marsan
authors.forename: D
authors.initials: D
authors.lastname: Lefatzis
authors.forename: A
authors.initials: A
authors.lastname: Pavlopoulos
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001442:Bacteroides Infections / Q000188:drug therapy; D001441:Bacteroides fragilis; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae; D006801:Humans; D008297:Male; D008875:Middle Aged; D001936:Moraxella catarrhalis; D016870:Neisseriaceae Infections / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy; D015575:Roxithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae
chemical_list: D000900:Anti-Bacterial Agents; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination